Abeona Therapeutics Inc. (ABEO)
NCM · Healthcare · Biotechnology
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
About Abeona Therapeutics Inc.
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in Cleveland, Ohio.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 400K | 0.00 | 5.4M | 8.7M |
| Gross Profit | 300K | -488K | 2.6M | 6.0M |
| Operating Income | -22.8M | -24.0M | -22.9M | -23.0M |
| Net Income | 108.8M | -5.2M | -20.5M | -17.1M |
| Diluted EPS | $1.71 | $-0.10 | $nan | $-0.30 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 1.4M | 3.5M | 0.00 | 5.8M |
| Gross Profit | 964K | 1.9M | 0.00 | 2.4M |
| Operating Income | -45.3M | -48.2M | -64.2M | -89.4M |
| Net Income | -39.7M | -54.2M | -63.7M | 71.2M |
| Diluted EPS | $-5.53 | $-2.53 | $-1.55 | $1.01 |